Kadcyla Manufacturing Review Was A Production In Itself
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The complex manufacturing required by Genentech’s antibody-drug conjugate trastuzumab emtansine pushed FDA’s review two months past the agency’s internal action timetable, required four review teams from three CDER offices and produced a veritable blizzard of information requests. But is that level of intensity sustainable as the expanding ADC pipeline matures?